PPARA and biliary liver cirrhosis: Fenofibrate, a PPAR-α agonist [8–12], bezafibrate, a panPPAR agonist [13–15], elafibranor, a dual PPAR-α and PPAR-δ agonist [16], saroglitazar, a dual PPAR-α and PPAR-γ agonist [17, 18], seladelpar (MBX-8025), a selective PPAR-δ agonist [19–21], have shown satisfying effect in decreasing markers of cholestasis and improving liver function in primary biliary cholangitis patients with incomplete UDCA response.